Mr Joe B Holden, MD | |
421 North Avenue F, Crowley, LA 70526 | |
(337) 788-0832 | |
(337) 783-6210 |
Full Name | Mr Joe B Holden |
---|---|
Gender | Male |
Speciality | General Practice |
Location | 421 North Avenue F, Crowley, Louisiana |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1427020825 | NPI | - | NPPES |
52065 | Other | LA | MEDICARE ID |
1027359 | Medicaid | LA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208D00000X | General Practice | 007957 (Louisiana) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mr Joe B Holden, MD P.o. Box 2098, 421 North Avenue F, Crowley, LA 70526 Ph: (337) 788-0832 | Mr Joe B Holden, MD 421 North Avenue F, Crowley, LA 70526 Ph: (337) 788-0832 |
News Archive
"A United Nations nutrition report [.pdf] released [Monday] shows that progress has been made in recent years in addressing stunting in children, and calls for increased efforts to accelerate a response to a condition that affects some 165 million children across the world," the U.N. News Centre reports.
Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic tissues through targeted oxygen and other gas delivery, today announced the initiation of a Phase 2b study designed to evaluate the efficacy and safety of MP4OX treatment plus standard of care in severely injured trauma patients with lactic acidosis due to hemorrhagic shock.
Proper formation of the proteins that power heart and skeletal muscle seems to rely on a precise concentration of a "chaperone" protein known as UNC-45, according to a new study.
Angiotech Pharmaceuticals has announced that results from the REALITY Trial, a head-to-head trial sponsored by Cordis Corporation, comparing the JNJ CYPHER® stent and the TAXUS® stent, were presented at the American College of Cardiology Annual Scientific Session. The trial failed to meet its primary endpoint.
› Verified 8 days ago